American Society of Hematology

Fig. 2.

$Fig. 2. Cotreatment with SAHA and imatinib causes more decline in Bcr-Abl levels and apoptosis. / K562 (A) and LAMA-84 (B) cells were treated with the indicated concentration of SAHA and/or imatinib for 48 hours. Following this treatment, the percentage of annexin V–stained apoptotic cells was determined by flow cytometry. (C) Western blot analyses of Bcr-Abl, p-AKT, procaspase-3, PARP, and its cleaved product in the cell lysates from K562 and LAMA-84 cells, following treatment with the indicated concentrations of SAHA and/or imatinib for 48 hours. The levels of β-actin served as the loading control. (D) Western blot analyses of Bcr-Abl, Ac-histone H3, histone H3, PARP, and its cleaved product in the cell lysates from CD34+ leukemia progenitor cells, from patients who had developed imatinib-refractory CML-BC, following treatment with the indicated concentrations of SAHA for 24 hours.$

Cotreatment with SAHA and imatinib causes more decline in Bcr-Abl levels and apoptosis.

K562 (A) and LAMA-84 (B) cells were treated with the indicated concentration of SAHA and/or imatinib for 48 hours. Following this treatment, the percentage of annexin V–stained apoptotic cells was determined by flow cytometry. (C) Western blot analyses of Bcr-Abl, p-AKT, procaspase-3, PARP, and its cleaved product in the cell lysates from K562 and LAMA-84 cells, following treatment with the indicated concentrations of SAHA and/or imatinib for 48 hours. The levels of β-actin served as the loading control. (D) Western blot analyses of Bcr-Abl, Ac-histone H3, histone H3, PARP, and its cleaved product in the cell lysates from CD34⁺ leukemia progenitor cells, from patients who had developed imatinib-refractory CML-BC, following treatment with the indicated concentrations of SAHA for 24 hours.

This Feature Is Available To Subscribers Only